title: Treatment of prostatic carcinoma with cyproterone acetate.
abstract: Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was administered. Increasing skeletal metastases were observed in 6 patients, whereas significant reduction of metastases took place in 2 patients. Objective relief of stranguria was observed only in 3 patients. The amount of residual urine increased in 3 patients and was reduced in 5. In about one third of the patients, the prostate gland became smaller and softer. The acidic phosphatases decreased from pathological to normal values in 7 patients. There were no observed hepatic, renal or haemotological side-effects. However, serious cardio-vascular complications occurred in 6 patients, while arterial hypertension developed in 4. It is suggested that Cyproterone acetate cannot be recommended as the only kind of hormonal treatment of prostatic cancer.
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000284:Administration, Oral; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy; D003534:Cyproterone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011859:Radiography; D011877:Radionuclide Imaging; D014554:Urination
chemical_list: D003534:Cyproterone; D000135:Acid Phosphatase